Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Ultragenyx Pharma (RARE) Misses Q1 EPS by 43c
May 5, 2022 5:33 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.19), $0.43 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $79.9 million versus the consensus estimate of $83.65 million.
Cash balance of approximately $814 million as of March 31, 2022
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More